Research Signal – Source date 2022-10-06
An immune response can become louder without becoming more effective. Cells may release more inflammatory signals while losing some of their ability to multiply, coordinate, or control a pathogen. Cellular senescence helps explain part of this uncomfortable pairing, especially as immune defenses age or face persistent infection.
The review Cellular Senescence in Immunity against Infections, published October 6, 2022, examines how senescence affects immune cells and the tissues around them. It also considers whether therapies aimed at senescent cells could improve immune function. The review brings together observations in humans, experiments with human-derived cells, animal models, and therapeutic studies in several disease settings. Those settings are related, but they do not answer the same question about infection outcomes.
When cells stop dividing but keep sending signals
Cellular senescence is a state in which a cell permanently stops dividing after stress or damage. The review describes features associated with senescent cells, including changes in shape, increased lysosomal β-galactosidase activity, activation of proteins such as p15, p16, and p21, and greater resistance to programmed cell death. A senescent cell is no longer proliferating normally, but it is not necessarily silent.
Many senescent cells release a mixture of cytokines, chemokines, proteases, reactive oxygen species, metabolites, microRNAs, and extracellular vesicles. This collection is often called the senescence-associated secretory phenotype, or SASP. Its contents can influence nearby cells and tissues. As senescent cells accumulate with age, their continuing secretory activity can contribute to chronic, low-grade inflammation sometimes called inflammaging.
The important biological tension is that inflammatory activity and pathogen control are separate outcomes. Inflammation can recruit and activate immune defenses, but persistent inflammatory signaling can also disrupt the conditions needed for a coordinated response. A tissue may therefore contain more inflammatory communication while its immune cells respond less flexibly to a new challenge.
Aging changes immune cells and their surroundings
Immunosenescence is broader than cellular senescence inside an individual immune cell. The review describes two connected routes. Aging can directly affect immune cells, changing their ability to proliferate, respond to receptors, and maintain effective adaptive responses. At the same time, senescent cells in surrounding tissues can weaken local barriers and release signals that alter how immune cells behave.
One example discussed in the review involves senescent fibroblasts. Their inflammatory signals recruited monocytes, and this environment inhibited the activation and proliferation of tissue-resident memory T cells. The result was weaker antigen-specific immunity in that experimental setting. The finding illustrates why the immune system cannot be understood only by counting senescent lymphocytes. A nonimmune tissue cell can help shape whether nearby immune cells perform effectively.
This age-related remodeling is associated with greater susceptibility to infection, weaker vaccination responses, dysregulated inflammation, and other changes in immune function. It does not mean that every older person has the same immune profile. The review emphasizes that immune aging varies substantially between individuals, which later becomes important for treatment design.
Infection can add pressure to an already changing system
The relationship between aging and infection runs in both directions. Age can make it harder to resolve an infection, while persistent exposure to a pathogen can place continuing stress on immune cells. Some viruses replicate for long periods. Others remain latent, with little ongoing replication, but can reactivate under certain conditions. Either pattern can repeatedly expose the immune system to viral antigens.
Long-term antigen exposure can drive T-cell exhaustion, a state in which virus-specific T cells remain dependent on antigen stimulation and gradually lose important functions. The review connects repeated rounds of proliferation with telomere erosion and DNA damage responses. If damage is not repaired, a cell may undergo programmed death or reach a permanent loss of division capacity known as replicative senescence.
Exhaustion and senescence overlap in some features, but they are not interchangeable labels. Exhausted T cells can show impaired function during chronic antigen exposure. Replicative senescence refers specifically to a durable limit on cell division. For cells with unrepaired damage, the review suggests that differentiation state may influence whether they undergo programmed cell death or enter replicative senescence.
The reviewed examples also show why persistence alone does not predict one uniform cellular result. Varicella-zoster virus-specific T cells declined with age, lost functions, and displayed exhaustion-associated markers. Herpes simplex virus-specific T cells showed related exhaustion findings, yet the telomere lengths described in those cells were not significantly shortened. The viruses’ ability to remain hidden from immune surveillance was offered as one possible context for this difference. Persistent or latent infection can therefore reshape immunity without automatically producing the same form of replicative senescence in every responding cell.
Respiratory viruses reveal the gap between inflammation and control
Respiratory syncytial virus provides one concrete illustration of the age-related problem. In mice, aging impaired the RSV-specific CD8-positive T-cell response, and viral load was higher in aged animals even though antiviral type I interferon signaling in the lungs was also higher. In older humans, the review describes reduced numbers of RSV-specific CD4- and CD8-positive T cells and reduced interferon-gamma secretion by RSV-specific T cells.
These are different kinds of observations. The mouse findings connect age with a weaker virus-specific response and higher viral load in an experimental model. The human observations concern immune-cell numbers and cytokine secretion. They do not amount to one combined measurement, and neither should be treated as a direct demonstration that a senescence-targeting treatment prevents severe RSV disease in older adults.
The review places RSV alongside influenza and other respiratory viruses that can impose a substantial burden on older people. It also notes that responses to several of these viruses remain less well understood. Shared immune pathways may make findings from RSV or influenza models informative for related questions, but an analogy between pathways is not the same as proof of an identical clinical process.
A marker is not a verdict about a cell
Potential treatment begins with a difficult identification problem. Researchers need to distinguish cells that are genuinely driving harmful senescent effects from cells that are highly differentiated, temporarily activated, or performing an important immune role. A single senescence-associated feature cannot automatically make that distinction.
The review discusses markers such as senescence-associated β-galactosidase activity, p16 expression, p21, and phosphorylated histone H2AX. High β-gal activity has been observed in several aged immune-cell populations, including T and B lymphocytes, plasmacytoid dendritic cells, natural killer cells, and monocytes. In human T cells, β-gal activity and p16 expression have been associated with age and disease. These measurements can help identify a population of interest, but they are not exclusive identity tags for every senescent immune cell.
The ambiguity is especially clear with macrophages. β-gal-based approaches may not reliably distinguish senescent macrophages from activated macrophages. That matters because an activated cell can be responding to a real threat, while an unwanted senescent cell may be contributing to persistent inflammatory signaling. Removing both would change the immune system in ways that are difficult to predict.
One mouse study discussed in the review used a prodrug processed by β-gal and observed reduced inflammation and improved physical function, with part of the effect attributed to depletion of β-gal-positive macrophages. The result is relevant to the possibility of selective elimination, but it does not establish a universal marker or an infection treatment for people. Classification is a biological problem before it is a drug-delivery problem.
Three treatment ideas pursue different changes
The review groups senescence-directed strategies into distinct categories. Senolytics are intended to remove senescent cells, often by making them more vulnerable to cell death. Senomorphics aim to alter the senescent secretory phenotype without killing the cell. A third approach targets exhausted immune cells and tries to restore useful function rather than eliminating them.
These goals should not be collapsed into one idea of “rejuvenating” immunity. Removing a senescent cell changes which cells remain. Modifying its secretions changes the signals reaching neighboring cells. Restoring an exhausted T cell changes how that cell responds to antigen and signaling pathways. Each intervention could produce a different balance of benefit and risk.
The review describes receptor blockade as an example of the third approach. In vitro, blocking PD-1 pathways restored effector functions in HIV-specific CD8-positive T cells and improved pathogen control in the experimental system described. In SIV-infected macaques, anti-PD-1 antibody expanded virus-specific CD8-positive T cells, increased their functionality, reduced plasma SIV RNA, prolonged survival, and reduced markers of immune activation. Anti-PD-L1 treatment in HIV-infected humanized mice reduced viral replication and increased CD4- and CD8-positive T-cell numbers.
These findings concern receptor blockade in specified experimental settings. They are not evidence that every exhausted cell should be activated, nor that restoring T-cell activity is equivalent to removing senescent cells. The biological aim is different: one strategy changes inhibitory signaling and cellular function, while another seeks to eliminate cells or dampen the signals they release.
Useful defenses can be caught in the crossfire
Senescent-cell biology is woven into pathways that also support normal immune development and response. The review describes adverse effects in animal studies and warns that suppressing inflammatory signaling can interfere with useful immune functions. Inhibition of the NF-κB pathway, for example, has been associated in the reviewed work with impaired development of mature lymphocytes and lymphoid progenitors, effects on thymocytes, macrophages, and B cells, and reduced lymphocyte growth or cytokine production. Some findings also raise concern about increased susceptibility to infection.
The opposite direction carries its own danger. Strongly stimulating a weakened immune system could produce acute inflammation or autoimmune disease. Trying to reduce inflammaging too broadly could leave the host less able to respond to pathogens. The practical problem is not simply to turn inflammation up or down. It is to change a harmful component while preserving the immune activities that are still protective.
Translation adds another layer of uncertainty. Mouse models have been valuable for studying aging and senescence, but it remains unclear how fully they reproduce human senescence mechanisms and their effects on infection. Studies of circulating blood cells can track exhaustion and senescence-related changes in living people, yet they do not necessarily reveal what is happening in immune cells embedded in tissues. A treatment that changes a blood marker or a laboratory T-cell response still needs evidence that the change improves meaningful infection outcomes in humans.
The review points toward more detailed combinations of multiparametric analysis, high-resolution omics, systems biology, and large-scale data analysis. The purpose is not to create a single universal test, but to identify which cellular patterns matter in which people and tissues. The same therapy may not suit every older adult or every persistent infection.
What more selective treatments could mean for infection defense
More selective senescence therapies could eventually help older adults or people with persistent infections by reducing harmful senescent-cell effects while retaining useful immune responses. The possible route is conditional: researchers would need to identify the relevant cells or signals, deliver an intervention without disrupting protective immunity, and demonstrate meaningful benefit in humans with acceptable immune effects.
If those hurdles are met, removing a damaging cell population, moderating its secretions, or restoring the function of an exhausted T cell could become distinct ways to improve pathogen control rather than broad attempts to reset the immune system. The 2022 review supports this as a research possibility, not as an established treatment outcome. Its central lesson is that a more inflammatory immune environment is not automatically a better defended one, and that improving infection defense will depend on knowing which cells and signals should be changed.
Key Sources
- Primary source: Cellular Senescence in Immunity against Infections.
DOI or Journal Page · Review or Meta-Analysis · 2022-10-06
Keep exploring